TapImmune today announced that it has entered into security purchase agreements with certain institutional and accredited investors in connection with a private placement of its equity securities. The private placement will be led by New Enterprise Associates (NEA) with participation from Aisling Capital and Perceptive Advisors, among other new and existing investors.
TapImmune today announced that its President and CEO, Peter L. Hoang, will present at the Jefferies 2018 Global Healthcare Conference taking place June 5-8, 2018, in New York City.
TapImmune today announced that its President and CEO, Peter Hoang, will participate in a panel discussion and give a company presentation at the 2018 Sachs Associates Immuno-Oncology BD&L and Investment Forum, held June 1, 2018, at the Waldorf Astoria Chicago Hotel.
TapImmune to Host Investor Webinar on Thursday, May 24th to Discuss Proposed Merger with Marker Therapeutics and Its Transformational T Cell Therapy Platform
TapImmune Inc. (NASDAQ: TPIV) announced today that Peter Hoang, President and CEO, will host a video webinar and slide presentation to discuss the details of the proposed merger with Marker Therapeutics, Inc., on Thursday, May 24, 2018, at 4:05 p.m. EST. The webinar will be followed by a live Q&A session.
TapImmune Expands Scientific Advisory Board with Cancer Immunotherapy Pioneers James P. Allison, Ph.D., and Padmanee Sharma, M.D., Ph.D., from the MD Anderson Cancer Center
TapImmune today announced that it has expanded its recently formed Scientific Advisory Board (SAB), which will become effective in conjunction with the proposed merger between the Company and Marker Therapeutics, Inc., and will support the continued clinical development of the Company’s transformative, non-genetically engineered, multi-antigen T cell therapy platform.
TapImmune Creates Scientific Advisory Board to Support Clinical Development of Multi-Antigen Cell Therapy Platform
It is great to welcome renowned thought leaders Dr. Cliona M. Rooney, Dr. Helen Heslop, current president of the American Society for Gene and Cell Therapy, and former President of ASGCT, Dr. Malcolm Brenner to the Scientific Advisory Board that will become effective in conjunction with the proposed merger between TapImmune and Marker Therapeutics, Inc.
TapImmune to Host Investor Breakfast to Discuss Proposed Merger with Marker Therapeutics
TapImmune and Marker Therapeutics Announce Entry into Merger Agreement, Creating a Transformational Immuno-Oncology Platform
TapImmune has entered into a definitive merger agreement to acquire Marker Therapeutics, Inc.
TapImmune President & CEO, Peter Hoang, will be giving a company presentation at the 2018 NYC Oncology Investor
Conference on May 9th at 3:00pm ET.
TapImmune President & CEO, Peter Hoang, will be participating in a panel discussion and give a company presentation at the 2018 Disruptive Growth & Healthcare Conference on May 9th.